Literature DB >> 11067036

Cost-effectiveness analysis with defined budget: how to distribute resources for the prevention of cardiovascular disease?

L Lindholm1, C G Hallgren, K Boman, K Markgren, L Weinehall, J E Ogren.   

Abstract

The aim of the study was to undertake cost-effectiveness calculations subject to a defined budget. The setting chosen was the prevention of cardiovascular disease (CVD) by means of three intervention programmes in a Swedish county council. The population in the county was divided into subgroups according to risk level. For each subgroup the cost per years of life saved was calculated, as well as the annual budget claims. The budget available was defined as present direct cost in the programmes. The calculations resulted in a programming solution showing the optimal distribution of resources between the programmes. Also a league table was constructed and the cut-off value for a 'acceptable' cost-effectiveness was shown. The conclusion that can be drawn is that a combination of internationally published intervention results and local data regarding epidemiology and resource improves the accuracy and usefulness of cost-effectiveness ratios. However, the model presented is a first attempt containing only three interventions: the planned next phase is to integrate more interventions in the model.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 11067036     DOI: 10.1016/s0168-8510(99)00045-7

Source DB:  PubMed          Journal:  Health Policy        ISSN: 0168-8510            Impact factor:   2.980


  7 in total

Review 1.  Economic evaluations of cholesterol-lowering drugs: a critical and systematic review.

Authors:  Pearl D Gumbs; Monique W M Verschuren; Aukje K Mantel-Teeuwisse; Ardine G de Wit; Anthonius de Boer; Olaf H Klungel
Journal:  Pharmacoeconomics       Date:  2007       Impact factor: 4.981

2.  Cost-effectiveness league tables: valuable guidance for decision makers?

Authors:  Josephine Mauskopf; Frans Rutten; Warren Schonfeld
Journal:  Pharmacoeconomics       Date:  2003       Impact factor: 4.981

3.  [Theoretical model of a cost-effectiveness analysis of combined enalapril-nitrendipine therapy for treating hypertension].

Authors:  F Antoñanzas; M Velasco; I Abbas; C Pontes; J Delgadillo; M Terán
Journal:  Aten Primaria       Date:  2003       Impact factor: 1.137

Review 4.  Eptifibatide: a pharmacoeconomic review of its use in percutaneous coronary intervention and acute coronary syndromes.

Authors:  Greg L Plosker; Tim Ibbotson
Journal:  Pharmacoeconomics       Date:  2003       Impact factor: 4.981

5.  Thresholds for the cost-effectiveness of interventions: alternative approaches.

Authors:  Elliot Marseille; Bruce Larson; Dhruv S Kazi; James G Kahn; Sydney Rosen
Journal:  Bull World Health Organ       Date:  2014-12-15       Impact factor: 9.408

6.  Rethinking cost-effectiveness in the era of zero healthcare spending growth.

Authors:  Ronen Arbel; Dan Greenberg
Journal:  Int J Equity Health       Date:  2016-02-24

7.  Does productivity influence priority setting? A case study from the field of CVD prevention.

Authors:  Lars Lindholm; Emil Löfroth; Måns Rosén
Journal:  Cost Eff Resour Alloc       Date:  2008-03-17
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.